Back to top
more

AnaptysBio (ANAB)

(Delayed Data from NSDQ)

$23.94 USD

23.94
292,681

+0.29 (1.23%)

Updated May 31, 2024 04:00 PM ET

After-Market: $23.95 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ANAB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

AnaptysBio, Inc. [ANAB]

Reports for Purchase

Showing records 41 - 60 ( 156 total )

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 41

03/22/2022

Daily Note

Pages: 4

Strategic Review Under New Leadership; Pipeline Assumptions Steady for Now

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 42

03/22/2022

Daily Note

Pages: 4

AnaptysBio - In Surprise Move, CEO Hamza Suria Departs, Interim CEO is Former Mirati COO, Spark CBO

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 43

03/15/2022

Daily Note

Pages: 5

ACORN Phase 2 Trial Setback; Imsidolimab Does Not Improve Acne; Reiterate Buy and $46 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 44

03/15/2022

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 45

03/14/2022

Company Report

Pages: 7

The Squirrel Lost This ACORN

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 46

03/07/2022

Company Report

Pages: 5

ANAB Looking for its ACORN this Spring

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 47

03/07/2022

Company Report

Pages: 5

ANAB looking for its ACORN this Spring

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 48

03/07/2022

Company Report

Pages: 5

Solid FY21 for AnaptysBio With Critical Catalysts in 2022; Reiterate Buy and Increase Our PT to $46 From $43

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 49

11/16/2021

Industry Report

Pages: 46

SITC 2021: Covered Companies Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 50

11/16/2021

Daily Note

Pages: 12

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 51

11/15/2021

Daily Note

Pages: 6

Rosnilimab Exhibits Favorable and Specific Anti-Inflammatory Responses in Healthy Volunteers; Reiterate Buy and $43 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 52

11/15/2021

Company Report

Pages: 4

Rosnilimab Shows Some Rosy Safety/PK Data in Healthy Volunteers

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 53

11/12/2021

Industry Report

Pages: 13

2021 Abstract Roundup For Covered CompaniesThis report contains brief updates on the following: ACET, ALPN, ANAB, BCEL, BEAM, CDAK, CTMX, FATE, IGMS, MRSN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 54

11/05/2021

Daily Note

Pages: 22

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 55

11/05/2021

Company Report

Pages: 6

Finished the GALLOP to GEMINI

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 56

11/05/2021

Company Report

Pages: 5

Solid 3Q21 Finish for AnaptysBio With Many Catalysts Ahead into 2022; Reiterate Buy and Maintain PT of $43

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 57

10/26/2021

Daily Note

Pages: 4

Shares Spike After Hours After New Royalty Purchase Agreement; Reiterate Buy and $43 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 58

10/26/2021

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 59

10/26/2021

Company Report

Pages: 6

Cash in Hand is Worth Dostarlimab Royalties in the Bush

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: AnaptysBio, Inc.

Industry: Medical - Biomedical and Genetics

Record: 60

10/04/2021

Daily Note

Pages: 8

Imsidolimab Shines at EADV with Impressive 16- Week Data (GALLOP); Reiterate Buy and $43 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 25.00

Research Provided by a Third Party